Genentech's Cabilly Patent, U.S. Patent No. 6331415, covers production of antibodies by producing both the light and the heavy chain of an antibody in a single host cell. The Cabilly patent is highly valuable to Genentech since it covers the main method by which antibodies are produced.
Genentech has shut down all IPRs against the Cabilly patent by settling with all petitioners whose IPR petitions were granted. Genentech settled before the PTAB made a decision on the merits.
Genentech has shut down all IPRs against the Cabilly patent by settling with all petitioners whose IPR petitions were granted. Genentech settled before the PTAB made a decision on the merits.
AIA Review #
|
Filing Date
|
Institution Decision Date
|
Petitioner
|
PO/Respondent Patent #
|
PO/Respondent
|
Status
|
Blog Notes
|
IPR2015-01624
|
07/27/2015
|
02/05/2016
|
Sanofi-Aventis U.S. LLC
|
6331415
|
Genentech, Inc.
|
Terminated
|
Genentech settled after the
institution of the IPR.
|
IPR2016-00383
|
12/30/2015
|
06/23/2016
|
GENZYME CORPORATION
|
6331415
|
Genentech Inc.
|
Terminated
|
The IPR petition was denied.
|
IPR2016-00460
|
01/15/2016
|
06/08/2016
|
Genzyme Corporation
|
6331415
|
GENENTECH, INC.
|
Terminated
|
Genentech settled after the institution
of the IPR.
|
IPR2016-00710
|
03/03/2016
|
09/08/2016
|
Mylan Pharmaceuticals Inc.
|
6331415
|
Genentech, Inc.
|
Terminated
|
Genentech settled after the
institution of the IPR.
|
IPR2016-01373
|
07/07/2016
|
01/03/2017
|
Merck Sharp & Dohme Corp.
|
6331415
|
Genentech, Inc.
|
Institution Denied
|
The IPR petition was denied.
|
IPR2017-00047
|
10/11/2016
|
01/03/2017
|
Merck Sharp & Dohme Corp.
|
6331415
|
Genentech, Inc.
|
Terminated
|
Genentech settled after the
institution of the IPR.
|
Other players in this filed, such as Celltrion, Amgen, or Pfizer, may now have no choice but to file an IPR petition against the Cabilly patent.
No comments:
Post a Comment